Kedrion Biopharma and Kamada Receive FDA Approval for KEDRAB
|
| |
|
In this Issue |
|
|
| • |
IVIG/Albumin Supply Index |
| • |
Open Market Pricing |
| • |
New Products from FFF |
| • |
Current Medicare
IVIG / SCIG Rates |
| • |
Resources |
| • |
Subscribe to IG Living and BioSupply Trends Quarterly |
|
|
|
|
|
|
| |
The U.S. Food and Drug Administration has approved Kedrion Biopharma’s and Kamada’s KEDRAB (rabies immune globulin [human]) for passive, transient postexposure prophylaxis of rabies infection when given immediately after contact with a rabid or possibly rabid animal and administered concurrently with a full course of rabies vaccine. [ read more ] |
|
Study Shows Increased Hospital Visits for Shingles Among Individuals Aged 20 to 59 Years
While emergency room visits for shingles has decreased for those vaccinated against either chicken pox (18 years to 19 years) or shingles (60 years and older), individuals aged 20 years to 59 years have experienced increased visits for the disease, according to a study. [ read more ] |
|
Study Shows Fever During Pregnancy Increases Risk of Autism at Birth
Researchers at Columbia University in New York have found children born to mothers who experience fever, especially multiple fevers, during the second trimester of pregnancy are at increased risk for developing autism spectrum disorder.
[ read more ]
|
|
|
